| Literature DB >> 32270964 |
Alexandre Cabral Zilli1, Solange Guizilini1, Isadora S Rocco1, José Amalth do Espírito Santo2, Otavio Berwanger2, Renato Abdala Karam Kalil3, Fabio Biscegli Jatene4, Alexandre Biasi Cavalcanti2, Renato Hideo Nakagawa Santos2, Walter J Gomes1.
Abstract
OBJECTIVE: To analyze the profile and outcomes of patients who underwent valve heart surgery in Brazil, using information retrieved from the Brazilian Registry of Cardiovascular Surgeries in Adults (BYPASS Registry) database.Entities:
Keywords: Access to Information; Aortic Valve; Cardiac Surgical Procedures; Heart Valve Diseases; Hospital Mortality; Public Health
Mesh:
Year: 2020 PMID: 32270964 PMCID: PMC7089740 DOI: 10.21470/1678-9741-2019-0408
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Fig. 1Flowchart of consecutive patients enrolled in the study. BYPASS Registry=Brazilian Registry of Cardiovascular Surgeries in Adults.
Preoperative demographic and clinical characteristics.
| Variables | Total (n=920) |
|---|---|
| Age (years), mean±SD | 56.7±15.8 |
| Sex (women), (n) % | (432) 47% |
| Type of health service system, (n) % | |
| The Brazilian National Health System (SUS) | 744 (80.8%) |
| Private | 176 (19.2%) |
| Preoperative comorbidity, (n) % | |
| Coronary artery disease, (n) % | 186 (20.2%) |
| Diabetes mellitus, (n) % | 159 (17.3%) |
| Dyslipidemia, (n) % | 243 (26.4%) |
| Hypertension, (n) % | 566 (61.5%) |
| Previous myocardial infarction, (n) % | 52 (5.7%) |
| Previous cardiovascular surgery, (n) % | 183 (19.9%) |
| Previous stroke, (n) % | 51 (5.5%) |
| Peripheral artery disease, (n) % | (37) 4% |
| Congestive heart failure, (n) % | (337) 36.6% |
| NYHA I | (17) 5% |
| NYHA II | (142) 42.1% |
| NYHA III | (134) 39.8% |
| NYHA IV | (44) 13.1% |
| LVEF < 40%, (n) % | (58) 6.3% |
| Chronic renal failure, (n) % | 49 (5.3%) |
| Dialytic, (n) % | 15 (1.6%) |
| Current smoking, (n) % | (78) 8.5% |
| COPD, (n) % | (96) 7.1% |
| Arrhythmia, (n) % | (207) 22.5% |
| Active endocarditis, (n) % | (56) 6.1% |
| EuroSCORE I – Log, mean ± SD | 7.9±10.4 |
| EuroSCORE II – Log, mean ± SD | 3.0±4.4 |
Data are shown as mean ± standard deviation (SD). COPD=chronic obstructive pulmonary disease; EuroSCORE=European System for Cardiac Operative Risk Evaluation; LVEF=left ventricular ejection fraction; NYHA=New York Heart Association; SUS=Sistema Único de Saúde
Fig. 2Relative frequency distribution of (A) ethiopathogeny and (B) cardiac operations by procedure type. AVR=aortic valve replacement; AVR+CABG=aortic valve replacement associated with coronary artery bypass surgery; AVR+MVRr=aortic valve replacement with mitral valve replacement or repair; MVr=mitral valve repair; MVr+CABG=mitral valve repair associated with coronary artery bypass surgery; MVR=mitral valve replacement; MVR+CABG=mitral valve replacement associated with coronary artery bypass surgery; MVRr+TVr=mitral valve replacement or repair associated with tricuspid valve repair; Others=other surgeries (including pulmonary valve surgery, aortic valve replacement associated with tricuspid valve repair and isolated tricuspid valve surgery).
Distribution of the surgical access performed and trans-operative complications.
| Variables | N=920 |
|---|---|
| Surgical access (n) % | |
| Conventional open surgery | (904) 98.3 |
| Minimally invasive | (15)1.6 |
| Robotic | (1) 0.1 |
| Trans-operative complications (n) % | |
| Major bleeding | (91) 9.9 |
| Blood products transfusion | (260) 28.3 |
| Post-perfusion syndrome | (10) 1.1 |
| Arrhythmia | (64) 7 |
| Myocardial infarction | (2) 0.2 |
| Low-output syndrome | (51) 5.5 |
| Use of vasopressors | (480) 52.2 |
| Trans-operative death | (10) 1.1 |
Postoperative complications and length of stay by surgery type and total.
| AVR | MVR | MVr | MVRr+ | AVR + | MVR + | MVr + | AVR + | Others | TOTAL | |
|---|---|---|---|---|---|---|---|---|---|---|
| Reoperation, (n) % | 12 (3.9%) | 3 (1.3%) | 1 (1.9%) | 0 (0%) | 2 (2.7%) | 0 (0%) | 2 (7.1%) | 5 (4.1%) | 0 (0%) | 25 (2.7%) |
| Major bleeding, (n) % | 15 (4.8%) | 11 (4.8%) | 1 (1.9%) | 2 (3.9%) | 1 (1.4%) | 0 (0%) | 0 (0%) | 8 (6.6%) | 2 (10%) | 40 (4.4%) |
| Mechanical ventilation (> 24 hours postoperatively), (n) % | 18 (5.8%) | 15 (6.6%) | 2 (3.8%) | 7 (13.7%) | 12 (16.2%) | 5 (19.2%) | 1 (3.6%) | 13 (10.7%) | 2 (10%) | 75 (8.2%) |
| Low-output syndrome, (n) % | 13 (4.2%) | 5 (2.2%) | 0 (0%) | 2 (3.9%) | 8 (10.8%) | 3 (11.5%) | 2 (7.1%) | 12 (9.9%) | 1 (5%) | 46 (5.1%) |
| Acute renal failure, (n) % | 13 (4.2%) | 6 (2.6%) | 2 (3.8%) | 3 (5.9%) | 7 (9.5%) | 2 (7.7%) | 2 (7.1%) | 6 (5%) | 1 (5%) | 4 (4.6%) |
| Coagulopathy, (n) % | 9 (2.9%) | 6 (2.6%) | 0 (0%) | 1 (2%) | 2 (2.7%) | 0 (0%) | 0 (0%) | 3 (2.5%) | 0 (0%) | 21 (2.3%) |
| Blood products transfusion, (n) % | 68 (21.9%) | 47 (20.7%) | 11 (20.8%) | 12 (23.5%) | 27 (36.5%) | 7 (26.9%) | 9 (32.1%) | 33 (27.3%) | 5 (25%) | 219 (24.1%) |
| Stroke, (n) % | 3 (1%) | 2 (0.9%) | 0 (0%) | 1 (2%) | 4 (5.4%) | 0 (0%) | 1 (3.6%) | 3 (2.5%) | 0 (0%) | 14 (1.5%) |
| Cardiac tamponade, (n) % | 0 (0%) | 2 (0.9%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 2 (0.2%) |
| Acute myocardial infarction, (n) % | 2 (0.6%) | 1 (0.4%) | 0 (0%) | 0 (0%) | 1 (1.4%) | 1 (3.8%) | 1 (3.6%) | 0 (0%) | 0 (0%) | 6 (0.7%) |
| Vasoplegic syndrome, (n) % | 3 (1%) | 0 (0%) | 0 (0%) | 1 (2%) | 3 (4.1%) | 0 (0%) | 2 (7.1%) | 0 (0%) | 0 (0%) | 9 (1%) |
| Postoperative length of stay (days, means), % | 12.5 ± 14.4 | 12.1 ± 8.1 | 9.2 ± 5.8 | 21.7 ± 21.7 | 11.1 ± 11.1 | 13.6 ± 8.6 | 11.8 ± 8.7 | 16 ± 10.7 | 16.8 ± 13.8 | 13.1 ± 12.4 |
Data from the patients who completed seven days of postoperative follow-up. AVR=aortic valve replacement; AVR+CABG=aortic valve replacement associated with coronary artery bypass surgery; AVR+MVRr=aortic valve replacement with mitral valve replacement or repair; MVr=mitral valve repair; MVr+CABG=mitral valve repair associated with coronary artery bypass surgery; MVR=mitral valve replacement; MVR+CABG=mitral valve replacement associated with coronary artery bypass surgery; MVRr+TVr=mitral valve replacement or repair associated with tricuspid valve repair; Others=other surgeries (including pulmonary valve surgery, aortic valve replacement associated with tricuspid valve repair, and isolated tricuspid valve surgery)
Fig. 3Observed mortality of patients who completed 30 days of postoperative follow-up versus predicted mortality by type of surgery. AVR=aortic valve replacement; AVR+CABG=aortic valve replacement associated with coronary artery bypass surgery; AVR+MVRr=aortic valve replacement with mitral valve replacement or repair; EuroSCORE=European System for Cardiac Operative Risk Evaluation; MVr=mitral valve repair; MVr+CABG=mitral valve repair associated with coronary artery bypass surgery; MVR=mitral valve replacement; MVR+CABG=Mitral valve replacement associated with coronary artery bypass surgery; MVRr+TVr=Mitral valve replacement or repair associated with tricuspid valve repair; Others=other surgeries (including pulmonary valve surgery, aortic valve replacement associated with tricuspid valve repair and isolated tricuspid valve surgery). Logistic EuroSCORE I and II are expressed in means by surgical type.
Fig. 4Observed mortality of patients who completed 30 days of postoperative follow-up versus predicted (EuroSCORE) due to valve disease etiology. EuroSCORE=European System for Cardiac Operative Risk Evaluation.
Comparison between the Brazilian BYPASS Registry study data and the STS Adult Cardiac Surgery Database 2019 data.
| AVR | AVR + CABG | MVR | MVR + CABG | MVr | MVr + CABG | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BYP | STS | BYP | STS | BYP | STS | BYP | STS | BYP | STS | BYP | STS | |
| 5.1 | 2.0 | 14.7 | 3.0 | 5.0 | 5.0 | 12.0 | 9.4 | 2.0 | 1.2 | 13.8 | 5.3 | |
| Reoperation, % | 3.9 | 4.6 | 2.7 | 6.8 | 1.3 | 8.8 | 0.0 | 11.7 | 1.9 | 4.2 | 7.1 | 7.4 |
| Stroke, % | 1.0 | 1.3 | 5.4 | 1.9 | 0.9 | 2.3 | 0.0 | 0.6 | 0.0 | 1.1 | 3.6 | 3.0 |
| Mechanical ventilation (> 24 hours postoperatively), % | 5.8 | 6.4 | 16.2 | 11.8 | 6.6 | 17.7 | 19.2 | 28.3 | 3.8 | 5.7 | 3.6 | 19.8 |
| Acute renal failure, % | 4.2 | 1.8 | 9.5 | 3.8 | 2.6 | 4.9 | 7.7 | 10.3 | 3.8 | 1.7 | 7.1 | 6.0 |
| Surgical site infection, % | 0.3 | 0.2 | 4.0 | 0.4 | 0.8 | 0.2 | 3.8 | 0.6 | 3.7 | 0.0 | 2.4 | 0.4 |
| Postoperative length of stay (days, means), % | 12.5 | 6.9 | 11.1 | 8.4 | 12.1 | 10.2 | 13.6 | 12.0 | 9.2 | 6.8 | 11.8 | 10.0 |
Operative mortality is defined by Society of Thoracic Surgeons (STS) databases as all deaths, regardless of cause, occurring during the hospitalization in which the operation was performed, even if after 30 days.
AVR=aortic valve replacement; AVR+CABG=aortic valve replacement associated with coronary artery bypass surgery; BYP=BYPASS Registry; BYPASS Registry=Brazilian Registry of Cardiovascular Surgeries in Adults; MVr=mitral valve repair; MVr+CABG=mitral valve repair associated with coronary artery bypass surgery; MVR=mitral valve replacement; MVR+CABG=mitral valve replacement associated with coronary artery bypass surgery
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| AVR | = Aortic valve replacement | MVR | = Mitral valve replacement | |
| AVR+CABG | = Aortic valve replacement + Coronary artery bypass grafting | MVR+CABG | = Mitral valve replacement + Coronary artery bypass grafting | |
| AVR+MVRr | = Aortic valve replacement + Mitral valve replacement or repair | MVRr+TVr | = Mitral valve replacement or repair + Tricuspid valve repair | |
| BSCVS | = Brazilian Society of Cardiovascular Surgery | NYHA | = New York Heart Association | |
| BYPASS Registry | = Brazilian Registry of Cardiovascular Surgery in Adults | RVD | = Rheumatic valve disease | |
| CABG | = Coronary artery bypass grafting | SAVR | = Surgical aortic valve replacement | |
| COPD | = Chronic obstructive pulmonary disease | SD | = Standard deviation | |
| DATASUS | = Departamento de Informática do SUS (the Brazilian Health Informatics Department) | STS | = Society of Thoracic Surgeons | |
| EACTS | = European Association of Cardiothoracic Surgery | SUS | = Sistema Único de Saúde (the Brazilian National Health System) | |
| EuroSCORE | = European System for Cardiac Operative Risk Evaluation | TAVR | = Transcatheter aortic valve replacement | |
| ICU | = Intensive care unit | TVr | = Tricuspid valve repair | |
| LVEF | = Left ventricular ejection fraction | VHD | = Valve heart diseases | |
| MVr | = Mitral valve repair | VHS | = Valve heart surgery | |
| MVr+CABG | = Mitral valve repair + Coronary artery bypass grafting | |||
| Authors' roles & responsibilities | |
|---|---|
| ACZ | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| SG | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| ISR | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |
| JAES | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| OB | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| RAKK | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| FBJ | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| ABC | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| RHNS | Substantial contributions to the acquisition of data for the work; final approval of the version to be published |
| WJG | Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; drafting the work or revising it critically for important intellectual content; final approval of the version to be published |